• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Atezolizumab may increase overall survival in patients with metastatic non-small-cell lung cancer

byHarsh ShahandDeepti Shroff Karhade
October 12, 2020
in Chronic Disease, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) and high programmed death 1 ligand (PD-L1) expression.

2. Atezolizumab was associated with longer progression-free survival compared to platinum-based combination chemotherapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The first line-treatment for advanced non-small-cell lung cancer (NSCLC) without mutations is inhibitors to programmed death 1 (PD-1) and its ligand PD-L1. Atezolizumab, an anti-PD-L1 monoclonal antibody, shows an overall survival benefit in participants with high PD-L1 expressing NSCLC tumors in Phase 2 studies. Even with the advances in treatment for metastatic NSCLC, additional treatments are needed. As such, this Phase 3 study evaluated the atezolizumab monotherapy in comparison to platinum-based chemotherapy for PD-L1 selected participants with metastatic NSCLC. The study results demonstrated that atezolizumab treatment significantly increased overall patient survival compared to platinum-based chemotherapy among participants with high PD-L1 expressing NSCLC tumors, regardless of histologic type. This randomized trial was limited by the additional biomarker analysis. The trial selected for participants with any expression level of PD-L1 from one particular assay. Therefore, additional biomarker analysis resulted from a double-selected patient population. Nonetheless, the results are significant, and the findings highlight the benefit of a different medication for participants with few treatment options.

Click to read the study in NEJM

Relevant Reading: Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer

In-Depth [randomized controlled trial]: This study enrolled 572 participants in a multicenter study at 144 locations in 19 countries. Participants included in the study had stage IV nonsquamous or squamous NSCLC, no previous chemotherapy, and PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells as determined by the SP142 assay. Participants with known epithelial growth factor receptor (EGFR) mutation of anaplastic lymphoma kinase (ALK) translocation were excluded from this study. The participants were randomized in a 1:1 ratio to receive 1200 milligrams, intravenously, of atezolizumab or 4 to 6 cycles of platinum-based chemotherapy every 3 weeks, respectively. The primary end point was overall survival. The median follow-up time for survival among participants with high PD-L1 expression was 15.7 months (range, 0 to 35). Among participants with high PD-L1 expressing tumors, the median overall survival in the atezolizumab group was significantly longer at 20.2 months compared to 13.1 months in the chemotherapy group (difference, 7.1 months; hazard ratio, 0.59; 95% confidence interval [CI], 0.40 to 0.89; P=0.01). In the subgroup with high or intermediate PD-L1 expressing tumors, the median overall survival between the two groups was not significant (atezolizumab group, 18.2 months; chemotherapy group, 14.9 months; hazard ratio, 0.72; 95% CI, 0.52 to 0.99; P=0.04). Similarly, there was no significant difference in the median overall survival between the two group with tumors that were not formally tested for PD-L1 expression (atezolizumab group, 17.5 months; chemotherapy group, 14.1 months; hazard ratio, 0.83; 95% CI, 0.65 to 1.07). At the end of follow-up, 146 of the 205 participants (71.2%) with high PD-L1 expressing tumors had disease progression or died. However, progression-free survival in the atezolizumab group was 8.1 months compared to 5.0 months in the chemotherapy group (hazard ratio, 0.63; 95% CI, 0.45 to 0.88). Finally, the safety analysis determined adverse events occurred in 90.2% of participants in the atezolizumab group and 94.7% of participants in the chemotherapy group. Specifically, Grade 3 or 4 adverse events occurred in the 30.1% of participants in the atezolizumab group and 52.5% of participants in the chemotherapy group with anemia, neutropenia, and thrombocytopenia being the most common. Taken together, atezolizumab monotherapy significantly increased overall survival in participants with high PD-L1 expressing metastatic NSCLC.

RELATED REPORTS

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Atezolizumabnon-small cell lung cancer (NSCLC)PD-1 inhibitorsprogrammed cell death protein 1 (PD-1)
Previous Post

Association between prehospital time and outcomes of trauma patients

Next Post

#VisualAbstract: Sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis patients

RelatedReports

Complement mutation linked to poor response to eculizumab
Oncology

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

May 23, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors
StudyGraphics

#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors

January 21, 2022
Next Post
#VisualAbstract: Sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis patients

#VisualAbstract: Sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis patients

#VisualAbstract: Early physical therapy effective in reducing disability for patients with lower back pain

#VisualAbstract: Active malignancy during COVID-19 infection not associated with increased risk of ICU admission, intubation, or death

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Low dose edoxaban prevents stroke in elderly patients with atrial fibrillation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.